Rafael Simó Canonge

This inventor holds 7 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Fundacio Hospital Universitari Vall D'hebron-Institut De Recerca, Bcn Peptides S.a., Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz. Active years: 2015-2024.

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 2.7

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Sant Cugat del Vallés, ES (2017)
Barcelona, ES (2015 - 2020)
Sant Cugat del Vallès, ES (2017 - 2024)

Company Filing History:

6 out of 17

Fundacio Hospital Universitari Vall D'hebron-Institut De Recerca

Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

patents

4. 1 out of 32

Universidad Autónoma De Madrid

patents

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11918577 - Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases (2024-03-05),

2. 11013738 - Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases (2021-05-25),

3. 10729634 - Sex hormone-binding globulin for use as a medicament (2020-08-04),

4. 10532082 - SOCS1-derived peptide for use in chronic complications of diabetes (2020-01-14),

5. 9707273 - Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role (2017-07-18),

6. 9631030 - Administering antibodies or fragments thereof which bind hemopexin for the treatment of ocular diseases (2017-04-25),

7. 9216208 - Topical ophthalmic peptide formulation (2015-12-22),

Title: Rafael Simó Canonge: Innovator in Retinal Neurodegenerative Disease Treatment

Introduction

Rafael Simó Canonge is a prominent inventor based in Barcelona, Spain. He has made significant contributions to the field of ophthalmology, particularly in the treatment of retinal neurodegenerative diseases. With a total of 7 patents to his name, his work focuses on innovative therapeutic approaches that aim to improve patient outcomes.

Latest Patents

One of Rafael's latest patents involves dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases. This invention relates to the use of inhibitors, including saxagliptin and sitagliptin, for the topical treatment and prevention of conditions such as diabetic retinopathy and its associated microvascular impairment. The invention also encompasses pharmaceutical topical eye compositions designed for these therapeutic applications.

Career Highlights

Throughout his career, Rafael has worked with notable institutions, including Fundació Hospital Universitari Vall D'Hebron - Institut De Recerca and Bcn Peptides S.A. His expertise in the field has allowed him to develop groundbreaking solutions that address critical health issues related to vision.

Collaborations

Rafael has collaborated with esteemed colleagues such as Cristina Hernández Pascual and Jimena Fernández Carneado. These partnerships have further enriched his research and development efforts, leading to advancements in the treatment of retinal diseases.

Conclusion

Rafael Simó Canonge stands out as an influential inventor in the realm of retinal neurodegenerative disease treatment. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient care.